RESEARCH ARTICLE a

Full list of author information is available at the end of the articleleukemia cells is a complex phenomenon undergoing several mechanisms. Background Doxorubicin, also known as hydroxydaunorubicin, is a drug commonly used in the treatment of a variety of cancers, es-pecially acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) [1]. However, resistance to doxorubicin is often observed in patients with leukemia, resulting in failure in chemotherapy. Such chemoresistance is a phenomenon found in many types of cancers including hematological malignancies (leukaemia and lymphoma), many kinds of carcinoma (solid tumors) and soft tissue sarcomas. Once the cancers develop chemoresistance to a distinct drug, they often display low sensitivity to a variety of other chemotherapy drugs and might not respond to these drug therapies, especially in the case of multi-drug resistance in chronic myelogenous leukemia (CML)